ClinicalTrials.gg
RecruitingNCT07567001HF-POLARISUpdated Aug 18, 2026

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

A Phase 3 interventional study of NNC0487-0111 and Placebo in Obesity and Heart Failure, sponsored by Novo Nordisk A/S. Recruiting at 838 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,610
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing zenagamtide in Obesity — 17 open to participants now, 20 under way, 14 of them phase 3. zenagamtide · Obesity.

Planned enrollment
2nd of 24
5,610 · median 360
Started
2026
with 18 others
Phase 3
14 of 24
11 open now
Primary completion
2029-07
later than 18 of 19 live
Registered
12th of 24
by date
Lead sponsor
24 of 24
Novo Nordisk A/S

Among the 24 studies testing zenagamtide in Obesity, this one is the 2nd largest by planned enrollment, is one of 19 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 18 of the 19 other live ones, and was the 12th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

17 of the 24 studies testing zenagamtide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About zenagamtide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing zenagamtide in Obesity, or all of them as a file.
02

Study summary

This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight. Participants will get NNC0487-0111 or placebo by injection once a week. Which treatment participants get is decided by chance. NNC0487-0111 is a new medicine that doctors cannot prescribe yet, but it has been tested in people before.

03

Conditions studied

  • Obesity
  • Heart Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) greater than or equal to (>=) 30 kilograms per square metre (kg/m\^2) at screening.
  • Diagnosis of HF with (NYHA) class II-IV and in stable condition at screening, at the discretion of the investigator.

For participants with Type 2 Diabetes (T2D) at screening:

- Diagnosed with T2D >= 30 days before screening.

Exclusion criteria

Exclusion Criteria:

  • MI, stroke, unstable angina pectoris or worsening HF leading to either hospitalization or intravenous loop diuretics within 30 days prior to the day of screening and until randomization.
  • HF due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, Chagas cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, or uncorrected primary valve disease of moderate or severe degree.
  • Severe pulmonary disease including primary pulmonary hypertension, chronic pulmonary embolism, or severe (COPD) defined as:
  • requiring home oxygen; or - ongoing oral therapy; or - hospital for COPD Exacerbation within 12 months prior to screening.
  • Any other condition judged by the investigator to be the cause of HF symptoms (e.g., anaemia, hypothyroidism).

Glycaemia-related:

  • History of type 1 diabetes.
  • Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or who, at the time of screening, are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • (HbA1c) greater than (>) 10 percent (%) (86 [millimoles per mole] mmol/mol) as measured by local or central laboratory at screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5,610 participants (estimated)

Study arms

  • Experimental
    NNC0487-0111

    Participants will receive NNC0487-0111 subcutaneously (s.c.) in a dose escalating manner once weekly.

    Drug: NNC0487-0111

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to NNC0487-011 s.c. once weekly.

    Drug: Placebo

Interventions

  • NNC0487-011 will be administered subcutaneously.

  • DrugPlacebo

    Placebo (matched to NNC0487-011) will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Time to first occurrence of a composite Heart Failure (HF) endpoint consisting of cardiovascular (CV) death

    Measured in days.

    Time frame: From baseline (week 0) to 165 weeks

  2. Time to first occurrence of a composite HF endpoint consisting of HF hospitalisation or urgent HF visit

    Measured in days.

    Time frame: From baseline (week 0) to 165 weeks

Secondary outcomes

  1. Time to first occurrence of a composite HF and Major Adverse Cardiovascular Events (MACE) end-point consisting of: CV death, HF hospitalisation or urgent HF visit, Nonfatal Myocardial Infraction (MI), Nonfatal stroke

    Measured in days.

    Time frame: From baseline (week 0) to 165 weeks

  2. Change in Clinical Summary Score of the Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS) for participants with baseline KCCQ-CSS score less than (<) 80 points

    Measured as score on scale. KCCQ measures Health-Related Quality of Life (HRQOL). Score ranges from 0 to 100, with 0 as the lowest score and 100 as the highest score. Higher scores indicate better health status, fewer symptoms and greater disease-specific HRQoL.

    Time frame: From baseline (week 0) to week 52

  3. Change in estimated Glomerular Filtration Rate (eGFR) (creatinine and cystatin C-based Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] 2021) for participants with baseline eGFR< 60 milliliter per minute per 1.73 square meter (mL/min/1.73 m^2)

    Measured as mL/min/1.73 m\^2.

    Time frame: From baseline (week 0) to week 78

  4. Time to all-cause death

    Measured in days.

    Time frame: From baseline (week 0) to 165 weeks

07

Study locations

530 of 838 sites recruiting
  • Advanced Cardiovascular, LLC
    Alexander City, Alabama 35010, United States
    Recruiting
  • Univ of Alabama Birmingham
    Birmingham, Alabama 35233, United States
    Not yet recruiting
  • Eastern Shore Rsrch Inst, LLC
    Fairhope, Alabama 36532, United States
    Recruiting
  • Mobile Heart USA Health Cardiology Clinic
    Mobile, Alabama 36608, United States
    Not yet recruiting
  • Mercy Gilbert Medical Center
    Gilbert, Arizona 85297, United States
    Recruiting
  • Sun City Clinical Research
    Glendale, Arizona 85304, United States
    Recruiting
  • Honor Health
    Phoenix, Arizona 85006, United States
    Not yet recruiting
  • Arizona Research Center
    Phoenix, Arizona 85016, United States
    Not yet recruiting
  • Arkansas Health Group
    Little Rock, Arkansas 72205, United States
    Not yet recruiting
  • InvivoCure -2
    Alhambra, California 91801, United States
    Recruiting
  • Cardio Research of S. Cal
    Beverly Hills, California 90210, United States
    Recruiting
  • Westside Medical Associates Los Angeles
    Beverly Hills, California 90211, United States
    Recruiting
  • Scripps Hospital
    Chula Vista, California 91910, United States
    Recruiting
  • John Muir Physicians Network
    Concord, California 94520, United States
    Recruiting
  • Valley Clinical Trials
    Covina, California 91723, United States
    Recruiting
  • Mission Cardiovascular Research Institute
    Fremont, California 94538, United States
    Recruiting
  • Amicis Research Center
    Granada Hills, California 91344, United States
    Recruiting
  • California Heart Specialist
    Huntington Beach, California 92648-1717, United States
    Recruiting
  • Valiance Clinical Research
    Huntington Park, California 90255, United States
    Recruiting
  • Joe C.Wen & Fam CTR for Adv Care
    Irvine, California 92612, United States
    Not yet recruiting
  • Scripps Memorial Hospital La Jolla
    La Jolla, California 92037, United States
    Not yet recruiting
  • UCSD NAFLD Research Center
    La Jolla, California 92037, United States
    Not yet recruiting
  • Cardio Innovation & Resch Ctr
    Long Beach, California 90813, United States
    Recruiting
  • Pacific Clinical Studies
    Los Alamitos, California 90720, United States
    Recruiting
  • VAGrtrLosAngelesHlthcareSystem
    Los Angeles, California 90073, United States
    Not yet recruiting
  • Amicis Research Center
    Northridge, California 91324, United States
    Recruiting
  • JPJ Research
    Northridge, California 91324, United States
    Recruiting
  • Valley Clinical Trials
    Northridge, California 91325, United States
    Recruiting
  • Desert Oasis Healthcare
    Palm Springs, California 92262, United States
    Recruiting
  • Empire Clin. Research
    Pomona, California 91767, United States
    Not yet recruiting
  • G&J Research
    San Diego, California 92117, United States
    Recruiting
  • San Diego Veterans Affairs
    San Diego, California 92161, United States
    Recruiting
  • Kaiser Permanente Northern California
    San Francisco, California 94118, United States
    Not yet recruiting
  • San Francisco V.A. Medical Center
    San Francisco, California 94121, United States
    Not yet recruiting
  • Fomat Medical Research
    Santa Maria, California 93454, United States
    Recruiting
  • NorthBay Clinical Research
    Santa Rosa, California 95405, United States
    Recruiting
  • St. Joseph's Medical Center
    Stockton, California 95204, United States
    Not yet recruiting
  • Valiance Clinical Research
    Tarzana, California 91356, United States
    Recruiting
  • Care Access Research
    Thousand Oaks, California 91360, United States
    Recruiting
  • InvivoCure
    Van Nuys, California 91405, United States
    Recruiting
  • Blue Coast Research Center
    Vista, California 92081, United States
    Recruiting
  • Interventional Cardiology Medical Group
    West Hills, California 91307, United States
    Recruiting
  • Univ of Colorado at Denver
    Aurora, Colorado 80045, United States
    Recruiting
  • VA Eastern Colorado Health Care System
    Aurora, Colorado 80045, United States
    Not yet recruiting
  • Intermountain Heart & Vascular
    Denver, Colorado 80218, United States
    Not yet recruiting
  • Colorado Heart and Vascular PC
    Golden, Colorado 80401, United States
    Recruiting
  • The GW Medical Faculty Associates
    Washington D.C., District of Columbia 20037, United States
    Not yet recruiting
  • BayCare Health System
    Clearwater, Florida 33756, United States
    Recruiting
  • Broward Research Ctr.
    Coral Gables, Florida 33134, United States
    Recruiting
  • Nature Coast Clinical Research
    Crystal River, Florida 34429, United States
    Recruiting
  • Arrow Clinical Trials
    Daytona Beach, Florida 32117, United States
    Recruiting
  • Inpatient Research Clinic LLC
    Florida City, Florida 33034, United States
    Recruiting
  • Jacksonville Ctr for Clin Res
    Jacksonville, Florida 32216, United States
    Recruiting
  • K2 Medical Research
    Maitland, Florida 32751, United States
    Recruiting
  • Total Research Group LLC
    Miami, Florida 33126, United States
    Recruiting
  • Infinite Clinical Research
    Miami, Florida 33133-4223, United States
    Recruiting
  • Future Life Clinical Trials
    Miami, Florida 33169, United States
    Recruiting
  • Broward Research Ctr.
    Miami Beach, Florida 33140, United States
    Recruiting
  • Inpatient Research Clinic LLC
    Miami Lakes, Florida 33014, United States
    Recruiting
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
    Recruiting
  • Ocala Cardiovascular Research
    Ocala, Florida 34471, United States
    Recruiting
  • Cardiovascular Institute of Orlando
    Orlando, Florida 32807, United States
    Recruiting
  • Ormond Beach Clinical Research
    Ormond Beach, Florida 32174, United States
    Recruiting
  • DBC Research - Pembroke Pines
    Pembroke Pines, Florida 33029-1406, United States
    Recruiting
  • SEC Clinical Research
    Pensacola, Florida 32503, United States
    Recruiting
  • Clearwater Cardiovascular Consultants
    Safety Harbor, Florida 34695, United States
    Recruiting
  • Intercoastal Medical Group
    Sarasota, Florida 34239, United States
    Not yet recruiting
  • St Joseph's Hospital Foundation
    Tampa, Florida 33607, United States
    Recruiting
  • Tampa Cardiovascular Interventions and Research
    Tampa, Florida 33614, United States
    Recruiting
  • Hope Research Network
    Virginia Gardens, Florida 33166, United States
    Recruiting
  • Guardian Research Org LLC
    Winter Park, Florida 32792, United States
    Recruiting
  • American Clinical Trials, LLC
    Acworth, Georgia 30101, United States
    Recruiting
  • Atlanta Center for Clinical Research_Atlanta
    Atlanta, Georgia 30342, United States
    Recruiting
  • East Atlanta Cardiology
    Conyers, Georgia 30012, United States
    Recruiting
  • Hope Clin Res & Wellness
    Conyers, Georgia 30094, United States
    Recruiting
  • Northeast Georgia Medical Ctr
    Gainesville, Georgia 30501, United States
    Recruiting
  • NSC Research, Inc
    Johns Creek, Georgia 30024, United States
    Recruiting
  • Peachtree Cardiology
    Peachtree, Georgia 30269, United States
    Recruiting
  • Cardiovascular Consultants of South Georgia
    Thomasville, Georgia 31792, United States
    Recruiting
  • Atlanta Heart Specialists, LLC
    Tucker, Georgia 30084, United States
    Recruiting
  • The Queen's Medical Center
    Honolulu, Hawaii 96813, United States
    Not yet recruiting
  • High Desert Heart and Vascular PLLC
    Meridian, Idaho 83642, United States
    Not yet recruiting
  • St. Luke's Idaho Cardiology Associates
    Meridian, Idaho 83642, United States
    Not yet recruiting
  • Chicago Clinical Research Institute INC
    Chicago, Illinois 60607, United States
    Recruiting
  • Univer Of Illinois at Chicago
    Chicago, Illinois 60612, United States
    Not yet recruiting
  • Eagle Clinical Research
    Chicago, Illinois 60621, United States
    Recruiting
  • Chicago Medical Research LLC
    Hazel Crest, Illinois 60429, United States
    Recruiting
  • Chicago Clinical Research Institute INC
    Orland Park, Illinois 60462, United States
    Recruiting
  • Methodist Medical Center of Illinois
    Peoria, Illinois 61603, United States
    Recruiting
  • Asha Clinical Rsch-Munster, LLC
    Hammond, Indiana 46324, United States
    Recruiting
  • Indiana University Health Methodist Hospital
    Indianapolis, Indiana 46202, United States
    Recruiting
  • Midwest Cardiovascu Rsrch Foundation
    Davenport, Iowa 52801, United States
    Not yet recruiting
  • University OF Iowa
    Iowa City, Iowa 52242, United States
    Not yet recruiting
  • West Houston Area Clinical Trial Consultants
    Wichita, Kansas 67226, United States
    Not yet recruiting
  • The Research Group of Lexington LLC
    Lexington, Kentucky 40503, United States
    Recruiting
  • UofL Health Care Outpatient
    Louisville, Kentucky 40202, United States
    Not yet recruiting
  • Research Integrity Global, LLC
    Owensboro, Kentucky 42303, United States
    Recruiting
  • Grace Research, LLC
    Bossier City, Louisiana 71111, United States
    Recruiting
  • Horizon Research Group of Opelousas, LLC
    Eunice, Louisiana 70535, United States
    Recruiting
  • Cardiovascular Institute of the South
    Houma, Louisiana 70360-4413, United States
    Recruiting

Showing the first 100 of 838 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jul 2029, 38 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 38 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 5, 2026
StartActual
May 11, 2026
Primary completionEst.
Jul 23, 2029
CompletionEst.
Aug 15, 2029
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07567001
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 5, 2026
Start date
May 11, 2026
Primary completion
Jul 23, 2029 (estimated)
Completion
Aug 15, 2029 (estimated)
Last update
Aug 18, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zenagamtide

Start the discussion